Efficacy and safety of the fixed dose combination of cefepime and sulbactam

ISRCTN ISRCTN84455313
DOI https://doi.org/10.1186/ISRCTN84455313
Secondary identifying numbers venus/cefepime_sulbactam/082006A
Submission date
04/03/2008
Registration date
15/05/2008
Last edited
15/05/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Nitin Rathod
Scientific

Dr R N Cooper Municipal General Hospital
Ville Parle
Mumbai
400056
India

Email drnmrathod@hotmail.com

Study information

Study designOpen labelled, non-randomised, multicentric clinical trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleMulticentric, open labelled, non-randomised, clinical trial to assess efficacy and safety of the fixed dose combination of cefepime and sulbactam in complicated upper and lower tract infections
Study objectivesThe objectives were:
1. To study the efficacy of fixed dose combination of cefepime and sulbactam injections in in complicated upper and lower tract infections
2. To assess comaprative safety of study drug
Ethics approval(s)Ethics approval received from the National Ethic Committee, Ahembdabad on the 28th April 2007 (date of issue of letter: 2nd May 2007) (ref: NEC/04-2007/02/VENUS/CEFEPIME_SULBACTAM/082006A).
Health condition(s) or problem(s) studiedComplicated upper and lower tract infections
InterventionFixed dose combination of cefepime and sulbactam (1.5 g to 3 g, intravenous [i.v.] twice daily). Duration of treatment 7 to 10 days, followed for 7 days after the treatment.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Cefepime, sulbactam
Primary outcome measureImprovement in clinical and laboratory parameters, measured on day 0, day 3 and day 7 (completion of treatment).
Secondary outcome measuresTo observe incidence of adverse events as assessed by clinical evaluation and laboratory parameters, measured on day 0, day 3 and day 7 (completion of treatment).
Overall study start date01/05/2007
Completion date31/07/2007

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants102
Key inclusion criteria1. Participants aged greater than 18 years (n = 102), either sex
2. Suffering from lower respiratory tract infections caused by gram negative organisms including pseudomonas aeruginosa
Key exclusion criteria1. History of hypersensitivity reaction or any specific contraindication to beta lactams
2. Presence of hepatic or renal disorders
3. Pregnancy or lactation
4. History of hearing loss
5. Alcoholics
6. Previous history seizure
Date of first enrolment01/05/2007
Date of final enrolment31/07/2007

Locations

Countries of recruitment

  • India

Study participating centre

Dr R N Cooper Municipal General Hospital
Mumbai
400056
India

Sponsor information

Venus Remedies Limited (India)
Industry

51-52 Industrial Area
Phase - I
Panchkula, Haryana
134113
India

Email research@venusremedies.com
Website http://www.venusremedies.com
ROR logo "ROR" https://ror.org/0169rv113

Funders

Funder type

Industry

Venus Remedies Limited (India)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan